Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study
- PMID: 24401715
- DOI: 10.3945/ajcn.113.068890
Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study
Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world. Oral administration of synbiotic has been proposed as an effective treatment of NAFLD because of its modulating effect on the gut flora, which can influence the gut-liver axis.
Objective: The objective was to evaluate the effects of supplementation with synbiotic on hepatic fibrosis, liver enzymes, and inflammatory markers in patients with NAFLD.
Design: In a randomized, double-blind, placebo-controlled clinical trial conducted as a pilot study, 52 patients with NAFLD were supplemented twice daily for 28 wk with either a synbiotic or a placebo capsule. Both groups were advised to follow an energy-balanced diet and physical activity recommendations.
Results: At the end of the study, the alanine aminotransferase (ALT) concentration decreased in both groups; this reduction was significantly greater in the synbiotic group. At the end of the study, the following significant differences [means (95% CIs)] were seen between the synbiotic and placebo groups, respectively: ALT [-25.1 (-26.2, -24) compared with -7.29 (-9.5, -5.1) IU/L; P < 0.001], aspartate aminotransferase [-31.33 (-32.1, -30.5) compared with -7.94 (-11.1, -4.8) IU/L; P < 0.001], γ-glutamyltransferase [-15.08 (-15.5, -14.7) compared with -5.21 (-6.6, -3.9) IU/L; P < 0.001], high-sensitivity C-reactive protein [-2.3 (-3, -1.5) compared with -1.04 (-1.5, -0.6) mmol/L; P < 0.05], tumor necrosis factor-α [-1.4 (-1.7, -1.1) compared with -0.59 (-0.8, -0.3) mmol/L; P < 0.001], total nuclear factor κ-B p65 [-0.016 (-0.022, -0.011) compared with 0.001 (-0.004, -0.007) mmol/L; P < 0.001], and fibrosis score as determined by transient elastography [- 2.98 (-3.6, -2.37) compared with -0.77 (-1.32, -0.22) kPa; P < 0.001].
Conclusions: Synbiotic supplementation in addition to lifestyle modification is superior to lifestyle modification alone for the treatment of NAFLD, at least partially through attenuation of inflammatory markers in the body. Whether these effects will be sustained with longer treatment durations remains to be determined.
Trial registration: ClinicalTrials.gov NCT01791959.
Comment in
-
More evidence that probiotics may have a role in treating fatty liver disease.Am J Clin Nutr. 2014 Mar;99(3):425-6. doi: 10.3945/ajcn.113.082636. Epub 2014 Feb 5. Am J Clin Nutr. 2014. PMID: 24500146 No abstract available.
Similar articles
-
Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial.J Nutr. 2018 Aug 1;148(8):1276-1284. doi: 10.1093/jn/nxy088. J Nutr. 2018. PMID: 29931231 Clinical Trial.
-
Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial.Br J Nutr. 2017 Mar;117(5):662-668. doi: 10.1017/S0007114517000204. Epub 2017 Mar 27. Br J Nutr. 2017. PMID: 28345499 Clinical Trial.
-
Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.Nutr Res. 2014 Oct;34(10):837-43. doi: 10.1016/j.nutres.2014.09.005. Epub 2014 Sep 23. Nutr Res. 2014. PMID: 25311610 Clinical Trial.
-
Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.Gastroenterology. 2020 May;158(6):1597-1610.e7. doi: 10.1053/j.gastro.2020.01.031. Epub 2020 Jan 25. Gastroenterology. 2020. PMID: 31987796 Free PMC article. Clinical Trial.
-
A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach.Diabetes Metab Syndr. 2019 Sep-Oct;13(5):2917-2922. doi: 10.1016/j.dsx.2019.07.063. Epub 2019 Jul 31. Diabetes Metab Syndr. 2019. PMID: 31425956 Review.
Cited by
-
The Role of Gut Microbiota Modification in Nonalcoholic Fatty Liver Disease Treatment Strategies.Int J Hepatol. 2024 Oct 16;2024:4183880. doi: 10.1155/2024/4183880. eCollection 2024. Int J Hepatol. 2024. PMID: 39444759 Free PMC article. Review.
-
Probiotics and Non-Alcoholic Fatty Liver Disease: Unveiling the Mechanisms of Lactobacillus plantarum and Bifidobacterium bifidum in Modulating Lipid Metabolism, Inflammation, and Intestinal Barrier Integrity.Foods. 2024 Sep 21;13(18):2992. doi: 10.3390/foods13182992. Foods. 2024. PMID: 39335920 Free PMC article. Review.
-
Gut microbiome: A revolution in type II diabetes mellitus.World J Diabetes. 2024 Sep 15;15(9):1874-1888. doi: 10.4239/wjd.v15.i9.1874. World J Diabetes. 2024. PMID: 39280189 Free PMC article. Review.
-
Protection against fibrosis by a bacterial consortium in metabolic dysfunction-associated steatohepatitis and the role of amino acid metabolism.Gut Microbes. 2024 Jan-Dec;16(1):2399260. doi: 10.1080/19490976.2024.2399260. Epub 2024 Sep 6. Gut Microbes. 2024. PMID: 39239875 Free PMC article.
-
Effects of Synbiotic Administration on Gut Microbiome and Fecal Bile Acids in Dogs with Chronic Hepatobiliary Disease: A Randomized Case-Control Study.Vet Sci. 2024 Aug 10;11(8):364. doi: 10.3390/vetsci11080364. Vet Sci. 2024. PMID: 39195817 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials